| Pathophysiology and classification of iron overload diseases; update 2018 |
7 |
| On the way to in vitro platelet production |
7 |
| Platelet transfusion: Current challenges |
6 |
| Complement activation during intravascular hemolysis: Implication for sickle cell disease and hemolytic transfusion reactions |
6 |
| Red blood cell alloimmunization and delayed hemolytic transfusion reactions in patients with sickle cell disease |
6 |
| Rational and design of the T-STORHM Study: A prospective randomized trial comparing fresh whole blood to blood components for acutely bleeding trauma patients |
5 |
| Understanding the underlying motives and intention among Indian blood donors towards voluntary blood donation: A cross-sectional study |
5 |
| Transfusion-associated hazards: A revisit of their presentation |
5 |
| Platelet component transfusion and alloimmunization: Where do we stand? |
4 |
| The Dead Sea needs salt water ... massively bleeding patients need whole blood: The evolution of blood product resuscitation |
4 |
| Blood transfusion in burn patients: Triggers of transfusion in a referral burn center in Iran |
4 |
| Oxidative stress and antioxidant defenses during blood processing and storage of erythrocyte concentrates |
4 |
| Inherited platelet disorders : Management of the bleeding risk |
4 |
| Treatment of platelet concentrates and plasma with riboflavin and UV light: Impact in bacterial reduction |
3 |
| Platelet and TRALI: From blood component to organism |
3 |
| How to mitigate the risk of inducing transfusion-associated adverse reactions |
3 |
| How to reposition the benefice-risk balance to safely transfuse patients in non-vital situations? |
3 |
| Blood donations mode: Assessment of the Lebanese model |
3 |
| Towards the understanding of the UV light, riboflavin and additive solution contributions to the in vitro lesions observed in Mirasol (R)-treated platelets |
3 |
| Transfusion in the WHO African Region |
3 |
| Association between MTHFR 677C > T polymorphism and vascular complications in sickle cell disease: A meta-analysis |
2 |
| Pathogen inactivation/reduction technologies for platelet transfusion: Where do we stand? |
2 |
| Differentiation of human dendritic cell subsets for immune tolerance induction |
2 |
| Amotosalen-inactivated plasma is as equally well tolerated as quarantine plasma in patients undergoing large volume therapeutic plasma exchange |
2 |
| Spontaneous bleeding in thrombocytopenia: Is it really spontaneous? |
2 |
| Clinical presentation of delayed hemolytic transfusion reactions and hyperhemolysis in sickle cell disease |
2 |
| Challenges in preventing and treating hemolytic complications associated with red blood cell transfusion |
2 |
| Relevance and costs of RHD genotyping in women with a weak D phenotype |
2 |
| Human red blood cell polymorphisms prevalent in Colombian population and its protective role against malaria |
2 |
| Optimizing exchange transfusion for patients with severe Babesia divergens babesiosis: Therapeutically-Rational Exchange (T-REX) of M antigen-negative and/or S antigen-negative red blood cells should be evaluated now |
1 |
| Red cell groups and Basque population(s): From anthropology to public health |
1 |
| Appropriate use of red blood cell transfusion in the emergency department before and after a specific protocol |
1 |
| Early initiation of extracorporeal photochemotherapy increases response for chronic graft versus host disease following steroid failure |
1 |
| How clinicians can minimize transfusion-related adverse events? |
1 |
| Plasma for direct therapeutic use, for today and tomorrow: A short critical overview |
1 |
| Prevention of delayed hemolytic transfusion reaction |
1 |
| Immuno-hematological findings in Delayed Reaction (DHTR) Hemolytic Transfusion |
1 |
| Can't get platelets to your bleeding patients? Just chill ... the solution is in your refrigerator! |
1 |
| Adaptation of platelet concentrates delivery to HAS/ANSM requirements evolution in EFS Grand-Est |
1 |
| Assessment of soluble platelet CD40L and CD62P during the preparation process and the storage of apheresis platelet concentrates: Absence of factors related to donors and donations |
1 |
| Unacknowledged adverse transfusion reactions: Are they a mine to dig? |
1 |
| Hemogram profile and interest of pre-donation hemoglobin measurement in blood donors in the northwest region of Morocco |
1 |
| Evaluating the effect of tariff on wastage and return of blood products in Kerman province |
1 |
| Transfusion-associated circulatory overload: A survey among Dutch intensive care fellows |
1 |
| Estimation of the hepatitis E assay-dependent seroprevalence among Croatian blood donors |
1 |
| International point prevalence study of Intensive Care Unit transfusion practices-Pilot study in the Netherlands |
1 |
| Nobel prize and the history of blood transfusion |
1 |
| Red blood cell alloimmunizations in beta-thalassemia patients in Casablanca/Morocco: Prevalence and risk factors |
1 |
| Human pegivirus-1 (HPgV-1) RNA prevalence and genotypes in volunteer blood donors from the Brazilian Amazon |
1 |
| Anti-HBc prevalence among Croatian blood donors in a 14-year period (2004-2017): Assessment of trends, risks and need for implementing routine testing |
1 |
